Previous PostUS Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell
Next PostMedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
